Liver aminotransferases in under-five HIV-positive children on HAART.

M O Ajulo, M K Omole, J O Moody, O T Dixon-Umo, O L Salami
{"title":"Liver aminotransferases in under-five HIV-positive children on HAART.","authors":"M O Ajulo,&nbsp;M K Omole,&nbsp;J O Moody,&nbsp;O T Dixon-Umo,&nbsp;O L Salami","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Higher mortality rates were reported in developing countries during early months of HAART initiation than in developed countries. The study aimed at assessing the effect of Highly Active Antiretroviral Therapy (HAART) on liver function of under-fives.</p><p><strong>Method: </strong>Two hundred and thirty-eight under-fives children were enrolled from five hospitals in Southern Nigeria. Ethical permission and written consent were obtained. Group A involved 91 seropositive-children on HAART regimen while Group B1 involved 24 seronegative-infants who received nevirapine from birth till age 6-week. Group B2 (18) and B3 (48) involved seronegative-children who received co-trimoxazole and were 6-month and 18-month old respectively. Group C involved 11 seropositive-children who received co-trimoxazole only. Group D involved 46 seronegative-children who served as the control group. A 2ml blood sample was obtained from each participant during first phase of the study and was analysed for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using kits manufactured by Randox. Group A children returned for second and third phases of the study after 3-month and 6-month respectively. Data were analysed by using ANOVA.</p><p><strong>Results: </strong>The results showed that ALT was highest in group A (12.8 ± 11.0 IU/L) suggesting hepatotoxicity while AST was highest in group B2 (35.4 ± 53.1 IU/L). Second phase, ALT and AST of group A were significantly reduced by 39.3% (p < 0.05), 29.9% (p < 0.05) respectively suggesting resolved hepatotoxicity. Third phase, ALT and AST were significantly reduced by .50.6% (p < 0.05) and 32.2% (p < 0.05) respectively suggesting resolved hepatotoxicity.</p><p><strong>Conclusion: </strong>Hepatotoxicity observed among HIV-infected children on HAART was resolved after 6-month of monitoring.</p>","PeriodicalId":7616,"journal":{"name":"African journal of medicine and medical sciences","volume":"44 3","pages":"197-204"},"PeriodicalIF":0.0000,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"African journal of medicine and medical sciences","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Higher mortality rates were reported in developing countries during early months of HAART initiation than in developed countries. The study aimed at assessing the effect of Highly Active Antiretroviral Therapy (HAART) on liver function of under-fives.

Method: Two hundred and thirty-eight under-fives children were enrolled from five hospitals in Southern Nigeria. Ethical permission and written consent were obtained. Group A involved 91 seropositive-children on HAART regimen while Group B1 involved 24 seronegative-infants who received nevirapine from birth till age 6-week. Group B2 (18) and B3 (48) involved seronegative-children who received co-trimoxazole and were 6-month and 18-month old respectively. Group C involved 11 seropositive-children who received co-trimoxazole only. Group D involved 46 seronegative-children who served as the control group. A 2ml blood sample was obtained from each participant during first phase of the study and was analysed for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) using kits manufactured by Randox. Group A children returned for second and third phases of the study after 3-month and 6-month respectively. Data were analysed by using ANOVA.

Results: The results showed that ALT was highest in group A (12.8 ± 11.0 IU/L) suggesting hepatotoxicity while AST was highest in group B2 (35.4 ± 53.1 IU/L). Second phase, ALT and AST of group A were significantly reduced by 39.3% (p < 0.05), 29.9% (p < 0.05) respectively suggesting resolved hepatotoxicity. Third phase, ALT and AST were significantly reduced by .50.6% (p < 0.05) and 32.2% (p < 0.05) respectively suggesting resolved hepatotoxicity.

Conclusion: Hepatotoxicity observed among HIV-infected children on HAART was resolved after 6-month of monitoring.

接受HAART治疗的5岁以下艾滋病毒阳性儿童的肝脏转氨酶。
背景:据报道,发展中国家在开始HAART治疗的最初几个月的死亡率高于发达国家。本研究旨在评估高效抗逆转录病毒治疗(HAART)对五岁以下儿童肝功能的影响。方法:对来自尼日利亚南部五家医院的238名五岁以下儿童进行了研究。获得伦理许可和书面同意。A组包括91名接受HAART治疗的血清阳性儿童,而B1组包括24名从出生到6周龄接受奈韦拉平治疗的血清阴性婴儿。B2组(18例)和B3组(48例)分别为6个月和18个月大的接受复方新诺明治疗的血清阴性儿童。C组11例血清阳性儿童仅接受复方新诺明治疗。D组46例血清阴性患儿作为对照组。在研究的第一阶段,从每位参与者身上采集2ml血液样本,并使用Randox生产的试剂盒分析丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)。A组患儿分别在3个月和6个月后返回进行第二和第三阶段的研究。数据分析采用方差分析。结果:A组ALT最高(12.8±11.0 IU/L)提示肝毒性,B2组AST最高(35.4±53.1 IU/L)。第二阶段,A组的ALT和AST分别显著降低39.3% (p < 0.05)和29.9% (p < 0.05),提示肝毒性得到缓解。第三期,ALT和AST分别显著降低了0.50.6% (p < 0.05)和32.2% (p < 0.05),提示肝毒性得到缓解。结论:hiv感染儿童接受HAART治疗6个月后肝毒性消失。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信